In 2017, Domain Therapeutics has incorporated SeaGull with three academic researchers from IRCC (Torino University). The asset centric company is aiming at leading to the clinic a mutated version of the Semaphorin 3A (SGL 10060) abled to reprogram the tumor microenvironment (TME). The TME is known to promote the tumorigenesis, to ease the dissemination of metastasis and offer an immunosuppressive context. In multiple in vivo models, SGL 10060 was shown to inhibit the release of metastasis, to potentiate the immune response and normalize the tumor vascularization. Backed to a strong IP, the program is entering regulatory preclinical development.
In 2017, Domain Therapeutics and Merck KGaA (Darmstadt, Germany) entered into collaboration and licensing agreement for the development of adenosine receptor antagonist drugs specifically designed for oncology and immuno-oncology. Merck will support research activities and gain worldwide rights to Domain Therapeutics’ next generation of adenosine receptor inhibitors. Under the terms of the agreement, Domain will be eligible for more than EUR 240 million in milestones, as well as undisclosed royalties.
In 2016, Domain Therapeutics and Medicxi, a Swiss venture fund dedicated to financing asset-centric companies, created Mavalon Therapeutics, a company focused on stopping the progression of Parkinson’s disease. Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson’s patients. GDNF is a naturally occurring factor promoting the growth of dopamine neurons. The drug candidate, a positive allosteric modulator of the metabotropic glutamate receptor type 3 (mGluR3 PAM), was discovered and initially developed by Domain Therapeutics with the support of the Michael J. Fox Foundation. Medixci committed up to €9m ($10m) in Mavalon.
In 2012, Domain Therapeutics has granted Prexton Therapeutics (Geneva - Switzerland) an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease. The chemical series was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono, a division of Merck (Darmstadt - Germany) in January 2011. Under the terms of the initial agreement between Domain Therapeutics and Prexton Therapeutics - a spin-off company of Merck Serono - Prexton benefited from an exclusive license option to progress the mGluR4 PAM drug candidates into clinical development. After having exercised the exclusive option, Prexton entered into license agreement with Domain Therapeutics, selected an mGluR4 PAM candidate, PXT002331, and conducted regulatory preclinical development and Phase I. In September 2016, Prexton announced the successful completion of the Phase I clinical trial.
In 2017, Prexton initiated a Phase II to assess the safety and effectiveness of Foliglurax. The company was acquired early in March 2018 by Lundbeck.
In 2012, Domain and Ono Pharmaceutical Co., Ltd. (Osaka - Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs). Under the agreement, Ono will pay to Domain Therapeutics upfront payment, research funding for the collaborative research programs, success-based milestones on the research and development progress, as well as royalties on sales of the products. Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.
In 2011, Domain Therapeutics signed an exclusive development and licensing agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease and other neurodegenerative diseases. Domain Therapeutics has contributed optimized compounds that have been developed from its proprietary chemical series. Under the terms of the agreement, the company has received EUR 2 million in upfront payment and research funding, and was eligible for up to EUR 132 million in milestones for the first two products, as well as undisclosed royalties.
In 2008, Domain Therapeutics signed a research agreement with Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company. Under the agreement, Domain Therapeutics applied its Dtect-All™ platform to identify novel drug candidates that target undisclosed G Protein-Coupled Receptors (GPCRs) of interest to Takeda. In 2009 Domain Therapeutics announced that it has successfully completed the first milestone in this research agreement with Takeda Pharmaceutical. Following milestone completion have not been publicly announced.